Recruiting

Anti-obesity Medication

Sponsor:

Texas Tech University

Code:

NCT06790160

Conditions

Obesity and Overweight

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The goal of this observational study is to learn about the real-world effects of selected obesity medications in adults undergoing medical weight management. The main outcomes of interest are changes in body composition, routine clinical markers, muscular performance, and nutritional intake over the course of treatment. Additionally, the influence of lifestyle factors on changes in these outcome variables will be examined.

Participants beginning treatment with selected obesity medications will undergo periodic body composition and muscular performance testing, as well as complete online surveys about their nutritional intake and physical activity and exercise participation. Additionally, routinely collected clinical information will be evaluated.

Conditions

Obesity and Overweight

Study ID

NCT06790160

Start date

Jan 31, 2025

Status verified date

May, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patient who is beginning treatment through Vineyard Virtual Health Clinic using semaglutide or tirzepatide. While the physician will individualize the treatment plans, the criteria for these medications will include, at a minimum: (A) a body mass index ≥30 kg/m2; OR (B) a BMI ≥27 kg/m2 plus at least one comorbidity.
  • Patient who lives in drivable proximity to a city with an accepted DXA testing facility and is willing to report to the facility for periodic body composition testing.

Exclusion Criteria:

  • Patients with type 2 diabetes.
  • Patients who report not being willing or able to complete the assessments included in this research study.
  • Patients who are currently pregnant or trying to become pregnant.

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Arms

Patients undergoing obesity treatment

This cohort will be comprised of individuals who are beginning obesity medication treatment at a specified virtual obesity medicine practice. Patients taking semaglutide or tirzepatide may be eligible for inclusion in this cohort.

Primary outcome measure

  • Change in Total Lean Soft Tissue [ Time Frame: From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline). ]
  • Change in Appendicular Lean Soft Tissue [ Time Frame: From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline). ]
  • Change in Total Fat Mass [ Time Frame: From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline). ]
  • Change in Handgrip Strength [ Time Frame: From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline). ]

Central Contacts and Locations

Central contacts

Grant Tinsley, Ph.D.

806-834-5895grant.tinsley@ttu.edu

Locations

Texas Tech University

Recruiting

Lubbock, Texas, United States, 79409

Contacts

Grant Tinsley

806-834-5895grant.tinsley@ttu.edu

More Information

Sponsor

Texas Tech University

Last update posted

May 15, 2026

Last verified

May, 2026

Keywords

  • obesity
  • GLP-1
  • body composition
  • nutrition
  • exercise

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Texas Tech University on 2026-05-15.